| Welcome
| Karl Mahler, Head of Investor Relations | PDF |
| Pharma Strategy: Sustainable growth by delivering more patient benefits at reduced cost to society
| Bill Anderson, Chief Executive Officer Roche Pharmaceuticals | PDF |
| Commercial Opportunities: Near-term growth drivers
| Teresa Graham, Head of Pharma Global Product Strategy | PDF |
| Late Stage Pipeline Oncology & Non-malignant Hematology
| Levi Garraway, Chief Medical Officer and Head Global Product Development | PDF |
| Late Stage Pipeline Neuroscience & Immunology
| Paulo Fontoura, Global Head of Neuroscience, Immunology, Ophthalmology, Infectious and Rare Diseases, Clinical Development | PDF |
| Late Stage Pipeline Ophthalmology
| Nilesh Mehta, Life Cycle Leader Faricimab | PDF |
| Late Stage Pipeline Infectious Diseases
| Barry Clinch, Global Head Infectious Diseases, Clinical Development | PDF |